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ABSTRACT
Introduction: Skin complications are a frequent side effect of oncological treatment, which may impair 
patients’ quality of life. The aim of this study is a subjective assessment of skin toxicity and life quality 
during anticancer treatment.
Material and methods: We analysed patients with malignant cancer, receiving conventional chemotherapy, 
molecularly targeted drugs, or both, between January 2019 and February 2020, for at least six weeks. The 
researchers’ questionnaire assessed the type and intensity of skin toxicity, its impact on the emotional 
state and life quality. Subjective needs concerning education about the potential toxicity of treatment and 
dermatological care were analysed. Global quality of life was assessed using the EORTC QLQ-C30 scale.
Results: We analysed 78 patients, aged 27–78 years (41 men; 37 women). Twelve patients received an-
ti-EGFR antibody. Skin toxicity influence on emotional state and life quality was assessed by age, gender, 
duration and type of therapy. Skin complications were reported by 95% of patients, 53% confirmed the 
influence of skin toxicity on emotional state and 32% on everyday functioning. The inverse correlation 
between life quality and skin lesions’ severity was found (correlation coefficient = 0,33, p < 0,0001). 31% 
of patients were willing to have a dermatologist in the team of leading doctors. 28% reported a total lack 
of possible skin side effects information. 82% declared total skin toxicity acceptance in case of the good 
effect of anti-cancer therapy.
Conclusions: Dermal toxicity negatively affects various areas of patient functioning. Improvement can be 
made by proper education of patients, effective prevention and treatment.
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factor receptor
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Systemic anticancer treatment may cause skin 
side effects in 40–90% of patients [1–3]. This mainly 
concerns molecularly targeted drugs. Monoclonal 
antibodies and tyrosine kinase inhibitors directed 
against the epidermal growth factor receptor (EGFR) 
cause skin toxicity in almost all treated patients [4, 5]. 
Immunotherapy in more than a third [6]. 
Skin toxicity may impair the quality of life, and if 
severe, lead to discontinuation of anticancer therapy. 
Patients should be properly prepared for potential ad-
verse effects which allow to effectively minimize the level 
of anxiety in the situation of their occurrence as well as 
improve compliance with medical recommendations. 
This study aims to subjectively evaluate skin toxicity 
in patients undergoing systemic treatment, its impact 
on their emotional state and quality of life. Moreover, 
the study assesses the extent to which patients are 
informed about potential complications as well as 
their needs for the prevention and treatment of these 
side effects.
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Stage 1 Recruitment of patients (1 year)






age, gender, education, employment, marital status, 
duration of therapy
Stage 2
Conducting questionnaire survey 
assessing skin toxicity
Detailed parts assessed:
 Impact on the
 life quality by 
EORTC QLQ-
C30 v.3
Impact on the 
emotional 
state and daily 
functioning
Type and severity 
of cutaneous 
toxicity 
Assessing prophylaxis. treatment 
and awareness of skin toxicity
Figure 1. The scheme of the course of the study
Material and methods 
This questionnaire survey was conducted between 
January 2019 and February 2020 in a group of cancer 
patients who received either palliative or adjuvant sys-
temic treatment for at least 6 weeks at the Department 
of Chemotherapy, Nicholas Copernicus Hospital, Lodz, 
Poland. Each patient gave informed consent for the 
survey. Bioethics committee approval for the study 
was obtained. 
An original questionnaire, consisting of three parts, 
was used to assess the type and severity of cutaneous 
toxicity and its impact on the emotional state and quality 
of life. In the first part — demographic: age, gender, 
education, employment, marital status and duration 
of therapy were analysed. In the second part patients’ 
global quality of life was assessed according to the 
standardized EORTC (European Organization for Re-
search and Treatment of Cancer) QLQ-C30 (Quality of 
Life Questionnaire Core 30) version 3. In the third part 
of the study adverse effects of skin and its appendages, 
occurring in the last month were analysed (in the initial 
version of the questionnaire 18 patients were asked 
about complaints occurring during the last week, but 
such a time interval was considered not representative 
of skin complications and was changed in subsequent 
questionnaires). Moreover, the influence of skin toxicity 
on emotional state and daily functioning was analysed. 
Prophylaxis and treatment of dermatological complica-
tions were assessed. The patients were asked about 
their knowledge of the possibility of dermal side effects 
and the possible need for dermatological consultation. 
The scheme of the course of the study is shown in 
Figure 1. 
Statistical significance of selected parameters was 
determined by chi-square test, Mann-Whitney U test 
and Kendall correlation, all tests were two-sided, no 
correction for multiple testing was applied.
Results 
78 patients (41 men, 37 women) were included in 
the study. Demographic data of the patients, information 
about the types of cancer and systemic treatment are 
presented in Table 1. 78% of the patients claimed that 
their feelings during cancer treatment should have the 
least negative impact on their daily life. 90% agreed that 
quality of life during chemotherapy was very important 
to them. The specific results of the quality of life using 
the EORTC QLQ-C30 questionnaire (version 3) are 
presented in Table 2. 
93% of patients reported the occurrence of side 
effects affecting the skin, its appendages and mucous 
membranes during systemic treatment. The results of 
the severity of these lesions are shown in Table 3. 
There was a positive correlation between the total 
quality of life scores and skin lesion severity (Kendall’s 
tau b = 0.33; p < 0.0001), indicating an association 
between worsening quality of life and greater severity 
of skin side effects. The relationship was confirmed by 
the chi-square test (analysis of subgroups separated 
by a median of total points), which showed that lower 
skin lesion severity was more likely to coexist with 
better quality of life (chi-square test p = 0.0003). The 
negative impact of skin toxicity on the emotional state 
was reported by 53% of patients, while 32% reported 
its impact on daily functioning. The results of examin-
ing the severity of this impact according to gender are 
shown in Table 4. The male group reported a statistical-
ly significant greater negative impact of skin side effects 
on emotional state compared to females (chi-square 
test p = 0.0007; Mann-Whitney test p = 0.0034). In the 
group of women, it is noteworthy that the adverse effect 
of skin lesions on daily functioning was numerically 
greater compared to men, but this difference was not 
statistically significant. 
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Table 1. Patient demographic data, information on types 
of cancer and applied systemic treatment






n = 41 (≈53%)







n = 34 (≈44%)
n = 30 (≈39%)
n = 14 (≈18%)




n = 15 (≈19%)




Less than 12 months
More than 12 months
n = 34 (≈44%) 




Less than 3 months
3–12 months 
1–3 years
More than 3 years
n = 34 (≈44%)
n = 31 (≈40%)
n = 10 (≈13%)











n = 38 (≈49%)
n = 11 (≈14%)
n = 5 (≈6%)
n = 5 (≈6%)
n = 4 (≈5%)
n = 4 (≈5%)  












n = 57 (≈73%)
n = 11 (≈14%)
n = 2 (≈3%)
n = 1 (≈1%)
n = 5 (≈6%)
n = 1 (≈1%)
n = 1 (≈1%)
* In addition, single patients with diagnosed cancer of: prostate, 
cervix, fallopian tube, oesophagus, nasopharynx, anus and pleural 
mesothelioma, uterine sarcoma, melanoma. 
**chemotherapy + cetuximab: n = 10; chemotherapy + panitu-
mumab: n = 1)
Table 2. The results of the quality of life study according 
to the EORTC QLQ-C30 (version 3) questionnaire
Quality of life of patients according to the EORTC QLQ-C30 
questionnaire (version 3)
Questions number 1–28, regarding the severity of factors 
impairing quality of life
Possible worsening  
of the quality of life 
with scores:
Possible range of point totals: 28–112
1 — Slightly
2 — Moderately
3 — Considerably 
4 — Extremely
Achieved range of total points: 29–80 
Median: 53 
Mean: 52.5
Question 29: How would you rate your general health over the 
past month? 
Badly — 2.6% of patients (n = 2) 
Rather bad — 3.8% (n = 3) 
Average — 52.6% (n = 41) 
Fairly well — 23.1% (n = 18) 
Good — 17.9% (n = 14)
Question 30: How would you rate your overall quality of life 
over the past month? 
Badly — 1.3% of patients (n = 1) 
Rather bad — 7.7% (n = 6) 
Average — 53.8% (n = 42) 
Fairly well —16.7% (n = 13) 
Good — 20.5% (n = 16)
Table 3. The results of the severity of adverse effects on 
the skin, its appendages and mucous membranes
The severity of adverse effects on the skin, its appendages 
and mucous membranes  
— 17 questions
Possible severity of 
side effects  
with scores:
Possible range of severity sum scores 
for side effects: 0–68
No change — 0 
A little — 2 
Moderately — 3 
Very much — 4
Achieved range of total points: 0–37
Median: 11 
Mean: 13.29 
No skin side effects: 7.7% of patients 
(n = 6)
As many as 28% of respondents reported being 
completely uninformed about possible skin-related 
side effects of anticancer treatment. Figure 2 shows 
data on the sources from which patients drew in-
formation about possible skin complications, for all 
respondents and according to the type of systemic 
treatment received. Only 44% of patients felt com-
pletely informed about possible skin toxicity. Among 
patients treated with EGFR inhibitors, the level of 
awareness was higher, with all of them reporting that 
they were completely (9/12) or moderately (3/12) 
informed about potential cutaneous side effects of 
anticancer treatment. In comparison, 58% of patients 
felt completely informed about the life-threatening side 
effects of anticancer treatment. 
As many as 82% of the respondents admitted that 
they were able to completely accept cutaneous side 
effects of treatment in case of a favourable result of the 
therapy and 18% of the patients would be able to accept 
them partially. As many as 55% declared that they did 
not receive recommendations from their doctor on how 
to prevent cutaneous side effects. In addition, 40% of 
patients who experienced skin toxicity said that their 
physician did not recommend them any treatment for 
skin lesions or did not inform them of the need to avoid 
factors that exacerbate symptoms. Figure 3 shows data 
on the frequency and type of recommendations given 
by the oncologist for prevention (3A) and treatment 
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Table 4. The influence of skin toxicity on the emotional state and functioning of patients
Females (n = 37) Males (n = 41)
6 questions regarding the negative impact on patients’ emotional state:
Possible negative 
impact scoring:
Possible range of point totals: 0–24 Possible range of point totals: 0–24
chi-square test  




0 — No impact
1 — Slightly
2 — Moderately
3 — Considerably 
4 — Extremely
•	 Achieved range of total points: 0–16 
•	 Average point totals: 2.08 
•	 No negative impact in 67.6% of women  
(n = 25)
•	 Achieved range of total points: 0–19 
•	 Average point totals: 4.76 
•	 No negative impact in 29.3% of men 
(n = 12)
5 questions regarding the negative impact on patient functioning
Possible negative  
impact scoring:
Possible range of point totals: 0–20 Possible range of point totals: 0–20
chi-square test  
p = 0.127; Mann-
Whitney test  
p = 0.1939
0 — No impact
1 — Slightly
2 — Moderately
3 — Considerably 
4 — Extremely
•	 Achieved range of total points: 0–12 
•	 Average point totals: 2.78 
•	 No negative impact in 59.5% of women  
(n = 22)
•	 Achieved range of total points: 0–18
•	 Average point totals: 2.20 
































Figure 2. Patients’ information sources about potential skin toxicity of the treatment, among patients with different types 
of treatment
(3B) of cutaneous side effects, according to the type of 
systemic therapy as well as data about the frequency of 
using preventive measures, if applied (3C). 
58% of respondents agreed that they could use 
an antibiotic long-term if it reduced the severity of skin 
lesions, and 83% expressed acceptance of long-term 
use of skin care creams or medicated ointments. Among 
those who experienced skin side effects, 6% considered 
intermittent interruption or termination of anticancer 
treatment because of high lesion severity. Dermatological 
consultation was ordered only once. Four patients (5%) 
saw a dermatologist regardless of the oncologist’s rec-
ommendation. 31% of respondents expressed the need 
for a dermatologist in the oncological treatment team. 
Discussion
The nature of cutaneous toxicity of systemic treat-
ment depends on the type of drugs and differs in path-
omechanism.
Baldness is most commonly caused by paclitaxel 
(> 80%), doxorubicin (60–100%), cyclophosphamide 
(> 60%) and fluorouracil (10–50%) [7].
Nail damage during the systemic treatment most 
commonly includes onycholysis, leukonychia and 
paronychia.  These complications affect almost half of 
patients treated with taxoids and 1/3 of patients receiv-
ing anti-EGFR antibodies [8]. In our study, brittleness, 
ingrown nails, inflammation and cracking of the skin 
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Figure 3A. Frequency of various recommendations for prophylaxis against skin toxicity depending on the type of 
systemic treatment
around the nails were observed in 31% of all patients 
and 83% of patients treated with anti-EGFR antibodies.
Hand-foot syndrome is observed in approximately 
10–60% of patients undergoing anticancer treatment 
and is most commonly a complication of treatment 
with capecitabine, liposomal doxorubicin, docetaxel 
and fluorouracil [9]. Grade G1-2 hand-foot syndrome 
presents with erythema, hyperkeratosis and swelling 
of the palmar surface of the hands and soles of the 
feet. Grade G3 is associated with skin exfoliation, 
Figure 3B. Types and frequency of recommendations for prophylaxis against skin toxicity, depending on the type of 
systemic treatment
104
MEDICAL RESEARCH JOURNAL 2021. vol. 6. no. 2
www.journals.viamedica.pl/medical_research_journal





















blistering, ulceration and pain which make self-care 
difficult [10].
Taxoids, in addition to affecting hair and nails, can 
also cause erythema and skin rash [11]. Anti-EGFR 
antibodies, panitumumab and cetuximab, interfere with 
keratinocyte function and stimulate a non-specific im-
mune response in the skin [12, 13]. Skin toxicity affects 
up to 97% of patients receiving these drugs together 
with chemotherapy and most commonly manifests as 
acne-like rash, dry and pruritic skin, periungual derma-
titis and erythematous lesions. A G3/4 grade rash is 
observed in approximately 20–40% of patients receiving 
chemotherapy and anti-EGFR antibody, and G3/4 grade 
nail toxicity in approximately 15% [12, 14]. All patients 
included in the present study who underwent combi-
nation chemotherapy with anti-EGFR antibody reported 
an acne-like rash of varying severity (G ≥ 3 in 27% of 
subjects), consistent with the expected frequency of 
this complication.
Dry skin was the most common skin complication 
reported by the patients, occurring in 63% of them. In 
the group treated with anti-EGFR antibodies, dry skin 
affected all patients (G ≥ 3 in 27%). In addition, 82% of 
patients receiving anti-EGFR antibody reported damage 
of nails and nail area, and 55% reported features of 
hand-foot syndrome. This high incidence of these side 
effects may have been because patients were receiving 
fluorouracil infusions at the same time.
Trastuzumab and pertuzumab antibodies are di-
rected against the HER2 receptor (human epidermal 
growth factor receptor, type 2) which is also expressed 
in keratinocytes. They may cause skin toxicity in the 
form of rash, dry skin and nail plate changes [15, 16].
Skin toxicity had a negative impact on the emotional 
state of more than half of the surveyed patients and daily 
functioning in more than one-third of them. The negative 
impact of skin lesions on the emotional state was twice 
higher in men compared to women (4.76 vs. 2.08). 
These findings suggest that male patients may need 
more support with education, prevention and treatment 
of skin toxicity compared to women.
However, in a study of 379 patients by Gandhi et al, it 
was women who were 5 times more likely (15% vs. 3%) 
than men to report negative effects of skin toxicity on 
their professional and private lives. This study also found 
that interpersonal relationships were mostly affected in 
patients receiving targeted treatment (26%) compared 
to chemotherapy (4%) and radiotherapy (5%). Similar 
results were obtained by Rosen et al. [5, 17].
According to Nikolaou et al. and Barrios et al. skin 
toxicity caused by targeted drugs is a more frequent 
reason for dose modification compared to standard che-
motherapy. This poses a risk of premature termination 
of anticancer therapy [18, 19]. The increasing availability 
of targeted therapy causes the proper management of 
skin toxicity to become an important issue.
In our study, patients with poorer quality of life were 
more likely to report increased skin complaints. The 
analysis of data from American and European centers 
concerning skin toxicity during systemic treatment 
confirms that skin complications may worsen the 
quality of life of patients [2, 5, 17]. Hackbarth et al. 
Figure 3C. Types and frequency of prophylaxis used against skin toxicity among patients on different systemic treatments
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evaluated 91 patients, 70% of whom declared that the 
occurrence of skin toxicity in the course of systemic 
treatment significantly limited their daily activity [2]. In 
a study conducted on 283 patients in 2007–2008, Rosen 
et al. showed that skin side effects related to targeted 
therapy have a negative impact on patients’ quality of 
life, especially on their emotions and daily functioning 
[5]. In a study by Gandhi et al. dry skin, nail changes 
and burning sensations had the greatest impact on the 
quality of life of patients undergoing systemic treatment 
[17]. Many studies that aimed to evaluate the relation-
ship between skin toxicity or its severity and quality of 
life have yielded inconclusive results [20–22]. Unger et 
al. demonstrated worsening of quality of life in patients 
receiving anti-EGFR antibody together with chemother-
apy when G ≥ 3 versus G1-2 complications occurred 
[23]. On the other hand, in a study by Peeters et al. 
paradoxically, patients with more severe skin toxicity 
during treatment with anti-EGFR antibody reported bet-
ter quality of life [24]. In the case of anti-EGFR therapy, 
this paradoxical relationship between reported quality 
of life and severity of skin symptoms may be related to 
patients’ awareness that the occurrence of skin toxicity 
is an expected effect of the drug proving its efficacy, 
which may be a supportive factor in the acceptance of 
side effects [25].
An important aspect is to properly inform patients 
about possible skin complications. In our center, only 
44% of the patients felt completely informed about the 
expected cutaneous toxicity of the treatment. Patients 
who received anti-EGFR antibodies appear to be better 
informed about potential skin toxicity compared to the 
rest. All of these subgroups declared that they were 
completely or moderately informed about potential cuta-
neous side effects of anticancer treatment. This may be 
related to physicians’ less awareness of the cutaneous 
toxicity of drugs other than anti-EGFR.
In a study by Gandhi et al., 67% reported that 
cutaneous side effects of therapy were more severe 
than they expected. They found that before treatment, 
47% of patients expressed significant concern about 
possible hair loss, 14% about skin irritation and 13% 
about dry skin. These results differed from those ob-
tained during treatment, where only 29% of patients 
were concerned about hair loss, while skin irritation 
and dryness were feared by 23% and 24% of patients, 
respectively [17]. The discrepancy may have resulted 
from the fact that patients did not receive sufficient 
information before treatment regarding possible cuta-
neous side effects.
Adequate education that reinforces a sense of 
control during developing complications may help 
maintain the quality of life of patients experiencing 
cutaneous toxicity. Frith et al. developed a 4-step 
strategy to improve patients’ acceptance of cutaneous 
side effects. This consists of anticipating, coming to 
terms with the inevitable, becoming ready and taking 
control. A patient who is prepared for the side effects of 
systemic treatment may have lower levels of anxiety and 
psychological distress when complications occur [26]. 
Having specific information about possible cutaneous 
toxicity is additionally associated with more accurate 
adherence to recommendations for prevention and 
treatment of complications and with better-reported 
quality of life [11].
The effectiveness of the treatment of cutaneous side 
effects, and thus the tolerance of anticancer treatment 
as well as the patients’ quality of life, can be improved 
by the collaboration between oncologists and derma-
tologists.
As many as 40% of the patients who reported skin 
side effects in this study stated that the oncologist 
neither initiated treatment of the lesions nor provided 
information on lifestyle modifications that could im-
prove the skin condition. This is probably due to the 
high proportion of adverse reactions, such as dry skin, 
which patients may not have reported during a routine 
medical examination.
The occurrence of G ≥ 3 skin toxicity is an indica-
tion for dermatological consultation, especially if no 
improvement is obtained after 1–2 weeks of treatment 
[27]. Only one patient of the 78 included in this study 
was referred to a dermatologist. At the same time, more 
than one-third of the respondents expressed the need 
for the presence of a physician of this specialty in the 
therapeutic team.
In a study by Gandhi et al., 16% of all patients 
who experienced skin complications were referred to 
a dermatologist and 54% of patients admitted that they 
would feel better if they had this option [17]. A study by 
Guerrero et al. involving 127 patients with cutaneous 
complications of therapy, showed that 51% of them 
had a change in the diagnosis of skin symptoms after 
consultation with a dermatologist, and 64% were recom-
mended with further dermatological interventions [28].
Dermatological consultation can be particularly 
helpful in cases of increased skin toxicity when the 
oncologist is inclined to discontinue systemic treatment 
for this reason. Barrios et al. analysed the medical data 
of 44 patients in whom discontinuation of anticancer 
treatment due to skin toxicity was considered. In the 
dermatological assessment, interruption of anticancer 
treatment was considered justified in only 6 of the 
44 cases [18].
Another study showed that the assessment of cuta-
neous toxicity made by oncologists and dermatologists 
was consistent in only 62% of cases. Oncologists had 
the greatest difficulty in naming and assessing the 
severity of skin lesions, dermatologists in classifying 
skin toxicity according to the NCI CTCAE criteria [29]. 
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Therefore, the presence of a dermatologist in the ther-
apeutic team to diagnose and treat skin complications 
during anticancer therapy is justified. Moreover, the use 
of a consistent nomenclature and a scale for assess-
ing the severity of skin lesions will further improve the 
management of cutaneous toxicity.
It has also been shown that skin toxicity, in addition 
to its impact on quality of life, is also associated with 
increased costs of patient hospitalization [27]. In a study 
by Phillips et al. at a US center, the median length of 
hospital stay for patients requiring dermatological con-
sultation was 6 days greater compared with patients 
not requiring medical intervention in this regard [30].
In the USA we can observe the development of 
a branch of medicine called “supportive oncodermatol-
ogy” which is an answer to the escalation of skin toxicity 
as a complication of systemic treatment. Similar actions 
in Polish conditions could positively influence the quality 
of life and effective therapy of patients.
Conclusions
This study shows that cutaneous toxicity is an 
important but underestimated side effect of systemic 
treatment, which is associated with a poorer quality of 
life and an adverse effect on a patient’s emotional state. 
We have demonstrated the need for greater involvement 
of medical (including nursing) staff in educating patients 
about possible skin toxicity, its prevention and treatment. 
Patients’ access to professional sources of infor-
mation, such as information brochures and websites, 
should also be increased. 
Although these goals seem to be satisfactorily 
achieved among patients treated with anti-EGFR 
antibodies, prevention and treatment of skin toxicity 
caused by chemotherapy and other targeted drugs 
remain a challenge. 
Education reinforces patients’ sense of control 
during the appearance of side effects and increases 
the chances of effective compliance, thus giving greater 
chances of successful treatment of skin toxicity. 
Conflict of interest: None.
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